title: [Analysis of diagnosis and treatment towards CHB patients complicated with fatty liver with complete virological response while biochemical suboptimal response].
abstract: OBJECTIVE
  To analyze the reason of biochemical suboptimal response in CHB patients with complete virological response after more than 2 years standard treatment with Nucleos(t)-ide analogs (NUCs).To evaluate the efficacy and safety profiles of bicyclol tablets plus on the basis of the original treatment and lifestyle intervention. in CHB patients complicated with fatty liver.
  
  
  METHODS
  In 40 patients with chronic hepatitis B meeting the inclusion criteria,the liver biopsy was conducted.And patients complicated with fatty liver were treated with bicyclol tablets (25 mg, t.i.d) additional consecutive 48 weeks. The changes of serum biochemistry indexes and liver fibrosis index were observed before and after treatment.
  
  
  RESULTS
  Among 40 patients, 27 were complicated with fatty liver(69.23%), fatty degree in liver cell and liver inflammatory were closely related to the advanced fibrosis (x² =4.746, P=0.029; x² =5.072, P=0.024). The expression of HBsAg in serum and liver tissue showed no correlation with the advanced fibrosis (x² = 0.273, P=0.601; x² = 0.020, P =0.887) After bicyclol tablets treatment, serum biochemistry of patients complicated with fatty liver significantly decreased (F=58.045, P =0.000), plasma GST-PX significantly increased (t=15.109, P =0.000), plasma MDA significantly decreased (t=-10.786, P=0.000); LSM significantly decreased (t=2.255, P=0.036; t =5.376, P =0.002).
  
  
  CONCLUSIONS
  For the antiviral purpose of guide treatment, CHB patients treated with Nucleos(t)-ide analogs (NUCs) with biochemical suboptimal response, other risk factors should be considered as early as possible. Bicyclol plus lifestyle intervention was effective for chronic hepatitis B combined fatty liver patients with poor biochemical responses.
authors.affiliation: Department of infectious diseases, China-Japan Friendship Hospital, Beijing 100029, China.
authors.forename: Shue
authors.initials: S
authors.lastname: Liu
authors.forename: Meina
authors.initials: M
authors.lastname: Hao
authors.forename: Yanan
authors.initials: Y
authors.lastname: Ren
authors.forename: Mai
authors.initials: M
authors.lastname: Han
authors.forename: Jia
authors.initials: J
authors.lastname: Si
authors.forename: Anlin
authors.initials: A
authors.lastname: Ma
mesh_terms: D000998:Antiviral Agents; D005234:Fatty Liver; D006514:Hepatitis B Surface Antigens; D019694:Hepatitis B, Chronic; D006801:Humans; D008103:Liver Cirrhosis
chemical_list: D000998:Antiviral Agents; D006514:Hepatitis B Surface Antigens